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Lymph Node Staging of Gastric Cancer Using
18F-FDG PET: A Comparison Study with CT
Mijin Yun, MD1; Joon Seok Lim, MD2; Sung Hoon Noh, MD3; Woo Jin Hyung, MD3; Jae Ho Cheong, MD3;
Jung Kyun Bong, PhD1; Arthur Cho, MD1; and Jong Doo Lee, MD1
1Division of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea; 2Department of Diagnostic Radiology, Yonsei
University College of Medicine, Seoul, Korea; and 3Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
This study was performed to compare 18F-FDG PET with CT for the
evaluation of primary tumors and lymph node metastases in gas-
tric cancer.Methods: Eighty-one patients (28 women and 53 men;
mean age, 56.6 y; age range; 32–82 y) who had undergone radical
(n  74) or palliative (n  7) gastrectomy and lymph node dissec-
tion for the management of gastric cancer were included. Preop-
erative 18F-FDG PET and CT were reviewed retrospectively for
primary tumors of the stomach and lymph node metastases. Any
increased 18F-FDG uptake exceeding that of the adjacent normal
gastric wall was considered positive for the primary tumor. Lymph
nodes were classified into 3 groups based on their anatomic sites.
Because perigastric lymph nodes (N1) were often not clearly dif-
ferentiated from primary tumors, N1 lymph node metastases were
determined when possible. Lymph nodes were considered posi-
tive or negative on the basis of the group as a whole. Final con-
clusions for primary tumors and lymph node metastases were
based on histopathologic specimens in all patients.Results: There
were 17 patients with early gastric cancer (EGC) and 64 patients
with advanced gastric cancer (AGC). For primary tumors, both PET
and CT showed a sensitivity of 47% (8/17) for EGC and 98%
(63/64) for AGC. The sensitivity of CT for N1 disease was signifi-
cantly higher than that of PET. 18F-FDG PET had a sensitivity,
specificity, and accuracy of 34% (11/32), 96% (47/49), and 72%
(58/81), respectively, for N2 metastases, whereas the correspond-
ing CT values were 44% (14/32), 86% (42/49), and 69% (56/81).
For N3 metastases, PET and CT had the same sensitivity, speci-
ficity, and accuracy: 50% (3/6), 99% (74/75), and 95% (77/81),
respectively. Overall, the sensitivity, specificity, and accuracy of
18F-FDG PET were not significantly different from those of CT for
primary tumors or for N2 and N3 metastases. Conclusion: 18F-
FDG PET is as accurate as CT for the detection of primary tumors
of either EGC or AGC. The low sensitivities of PET and CT were
insufficient to allow decision making on the extent of lymphade-
nectomy. In contrast, the high specificity of PET for N disease
appeared valuable, and the presence of N disease on PET may
have a clinically significant impact on the choice of initial therapy.
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At staging, one of the major contributions of 18F-FDG
PET is in the detection of unsuspected metastases, leading
to changes in therapeutic plans for patients with various
malignancies. T staging of primary tumors typically re-
quires a high-resolution anatomic imaging modality because
exquisite anatomic details are mandatory in deciding on the
surgical resectability of the primary tumors. Unlike ana-
tomic imaging, 18F-FDG PET may have a role in predicting
patient prognosis on the basis of the metabolic activity of
primary tumors (1). The role of 18F-FDG PET in N staging,
unlike T or M staging, seems to be difficult to elucidate
because not every lymph node can accurately be confirmed
histopathologically, and the evaluation of lymph nodes by
individual location or number may not always be possible
on 18F-FDG PET. Nevertheless, the superior accuracy of
18F-FDG PET, compared with conventional CT, has been
well established in the evaluation of mediastinal lymph
nodes in patients with non–small cell lung cancer (2). In
patients with squamous cell carcinoma of the esophagus,
18F-FDG PET has proven more sensitive but less specific
than CT for detecting lymph node metastases (3). The
results of 18F-FDG PET for the axillary staging of breast
cancer have been controversial, and sentinel lymph node
sampling has been reported to have the lowest number of
false-negative results (4). The value of 18F-FDG PET for
detecting lymph node involvement is rather limited in pa-
tients with osteosarcoma, because metastases to the lymph
nodes are rare in osteosarcoma tumors (5). The diagnostic
performance of 18F-FDG PET for lymph node staging seems
dependent on many factors, such as the avidity of primary
tumors for 18F-FDG, the frequency of lymph node metasta-
ses, the size of metastatic lymph nodes, and the prevalence
of chronic inflammatory diseases in certain areas. Thus, the
value of 18F-FDG PET in evaluating lymph node metastases
needs to be elucidated according to each type of malignant
tumor.
Accurate staging is essential for selecting preoperative
surgical strategies for gastric cancer. Adjacent organ in-
volvement, peritoneal carcinomatosis, and distant metasta-
ses are important factors for determining the surgical re-
sectability of disease. Although effective for detecting
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nonskeletal distant metastasis, 18F-FDG PET may not be the
most useful imaging modality for evaluating adjacent organ
invasion and peritoneal carcinomatosis (6). Unless paraaor-
tic lymph node metastasis is clearly evident, other extragas-
tric lymph node metastases may not affect the surgical
resectability of gastric cancer. However, lymph node stag-
ing is extremely important for planning the optimal extent
of lymphadenectomy. Although CT has been the modality
of choice, its accuracy is based solely on the size of lymph
nodes—a criterion that is insufficient to guide therapeutic
plans. Likewise, lymph node staging by other conventional
imaging modalities such as endoscopic ultrasonography and
MRI is considered insufficiently accurate for deciding on
the extent of lymphadenectomy. This retrospective study
was performed to compare the diagnostic performance of
18F-FDG PET with that of CT, mainly for detection of
lymph node metastases in patients with gastric cancer.
MATERIALS AND METHODS
Patients
Eighty-one patients (28 women and 53 men; mean age, 56.6 y;
age range; 32–82 y) who had undergone radical (n  74) or
palliative (n 7) gastrectomy and D2 (n 68), D3 (n 7), or D4
(n  6) lymph node dissection for the management of gastric
cancer were included in this study. D2 procedures were used for
dissection of lymph nodes at the N1 and N2 levels; D3 procedures,
for the N3 level; and D4 procedures, for the N4 level, in accor-
dance with the Japanese nodal staging system (7). Within 2 wk of
each other, preoperative 18F-FDG PET and CT were performed on
all patients, and the images were reviewed retrospectively for
evidence of primary tumors of the stomach and for lymph node
metastases. The primary tumors were categorized as early gastric
cancer (EGC), limited to the mucosa or mucosa and submucosa
(T1), or advanced gastric cancer (AGC), including T2, T3, or T4
tumors. No patient had undergone preoperative chemotherapy or
radiotherapy.
Imaging Procedures
For PET, patients fasted at least 4 h before the intravenous
injection of 18F-FDG, and scanning began 60 min afterward.
Images from the neck to the proximal thigh were obtained either
on an Advance PET scanner (GE Healthcare), with a spatial
resolution of 5 mm in the center of the field of view, or on an
Allegro PET scanner (Philips-ADAC Medical Systems), with a
spatial resolution of 5.3 mm in the center of the field of view. For
the Advance, approximately 370 MBq of 18F-FDG were intrave-
nously injected, and the emission scan was acquired for 5 min per
bed position in 2-dimensional mode. The Allegro acquired data in
3-dimensional mode after administration of 5.18 MBq (0.14
mCi)/kg of 18F-FDG. Transmission scans (3 min per bed position)
to correct for nonuniform attenuation were obtained using 68Ge for
the Advance or 137Cs point sources for the Allegro. Transmission
scans were interleaved between the multiple emission scans for the
Allegro. The images were reconstructed using an iterative recon-
struction algorithm, that is, either the ordered-subset expectation
maximization for the Advance or the low-action maximal-likeli-
hood algorithm for the Allegro.
CT of the abdomen and pelvis was performed on 1 of 3 scanners
(LightSpeed Plus or HiSpeed CT/I; GE Healthcare, or Sensation
16; Siemens) using reconstruction thicknesses of 3.75, 5, and 3
mm, respectively. Enhanced CT scans were obtained after a bolus
intravenous injection of a 60% w/v contrast medium (approxi-
mately 90% higher-osmolarity agents and 10% lower-osmolarity
agents) at 2–4 mL/s from a volume of 2 mL/kg up to a maximum
volume of 150 mL.
Data Analysis
Two experienced nuclear medicine physicians who were un-
aware of other clinical or imaging information read the 18F-FDG
PET images on a high-resolution computer screen. The readers
reached a consensus in cases of discrepancy. For primary tumors
of the stomach, any increased 18F-FDG uptake exceeding that of
the adjacent normal gastric wall was considered positive for ma-
lignancy. On the other hand, any mucosal irregularity, mass, or
focal or diffuse enhancement on CT was considered a primary
tumor. In addition, a region of interest was drawn over the site of
the most intense 18F-FDG uptake in the primary tumor, and the
average standardized uptake value (SUV) corrected for total body
weight was taken for semiquantitative analysis of PET. A mini-
mum region-of-interest diameter of 6 pixels was used in 2 patients
with EGC tumors measuring less than 1 cm. In patients with AGC,
histologic and macroscopic types of primary tumors were com-
pared using SUVs.
Abdominal lymph nodes were classified into 3 groups based on
anatomic location. The N1 group included perigastric lymph nodes
attached to the stomach; the N2 group included lymph nodes along
the left gastric artery, common hepatic artery, celiac artery, or
splenic artery or at the splenic hilum; and the N3 group included
lymph nodes in the hepatoduodenal ligament, retropancreatic ar-
tery, mesenteric artery, mid colic artery, or paraaortic regions.
According to the guidelines of the Japanese Research Society for
Gastric Cancer, lymph nodes along the mid colic artery and
paraaortic regions are classified as N4 (7). However, we combined
N3 and N4 groups into N3 for statistical purposes because there
were only a few lymph nodes in these groups. A lymph node with
18F-FDG uptake similar to or higher than that of the liver was
considered positive for metastasis. Because perigastric lymph
nodes (N1) were often not clearly differentiated from the primary
tumors, N1 metastasis was determined whenever possible. Any
lymph node of 8 mm or larger was considered metastatic on CT.
Lymph nodes were considered positive or negative on the basis of
the group as a whole, that is, positive if one or more lymph node
metastases were discernible in the group and negative if none was
discernible.
Final conclusions on the presence of lymph node metastases
were based on the results of histopathologic examination of spec-
imens. The absence of N3 disease could not be histopathologically
confirmed in this study because only 13 of the 81 patients under-
went D3 or D4 lymph node dissection. The following criteria were
used to verify the absence of N3 disease: no N3 lymph node found
on preoperative PET and CT, no lymph node enlargement found
during the operation, and no lymph node enlargement found on
follow-up CT.
Statistical Analysis
The sensitivity, specificity, accuracy, negative predictive value
(NPV), and positive predictive value (PPV) of each modality were
calculated for detection of primary tumors and lymph nodes ac-
cording to the groups. The 2 test was performed to determine
differences in diagnostic performance between the 2 imaging mo-
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dalities. Statistical significance was assumed when a P value was
less than 0.05.
In patients with AGC, histologic and macroscopic types of
primary tumors were compared with SUVs using the Student t test




The patient characteristics and pathologic data are sum-
marized in Table 1. There were 17 patients with EGC and
64 patients with AGC. Both PET and CT detected 47%
(8/17) of EGC and 98% (63/64) of AGC (Fig. 1). Of the 63
AGC tumors detected on PET, 5 showed only mildly in-
creased 18F-FDG uptake compared with that of the adjacent
gastric wall. The mean SUVs of the primary tumors were
2.8  1.6 (range, 1.6–3.3) for EGC and 7.9  8.0 (range,
1.9–55) for AGC.
Of the 64 patients with AGC, 36 had poorly differentiated
tubular adenocarcinoma (mean SUV, 6.8  5.5), 22 had
moderately differentiated tubular adenocarcinoma (mean
SUV, 10.5  11.3), 4 had signet ring carcinoma (mean
SUV, 4.1  0.9), 1 had well-differentiated tubular adeno-
carcinoma (SUV, 5.6), and 1 had lymphoepitheliomalike
carcinoma (SUV, 5.4). Statistical analysis was performed
only between moderately differentiated and poorly differ-
entiated tubular adenocarcinomas because the numbers of
cases for the rest of the histologic types seemed insufficient.
Although the mean SUV of moderately differentiated tubu-
lar adenocarcinoma appeared to be higher than that of
poorly differentiated tumors, the difference was not statis-
tically significant.
AGC tumors were categorized according to macroscopic
types of primary tumors. There were 9 polypoid tumors
(type I; n 9; mean SUV, 18.6 15.9), 21 ulcerofungating
tumors (type II; n  21; mean SUV, 7  3.9), 22 ulcero-
infiltrative tumors (type III; n  22; mean SUV, 6.2  4.2),
and 12 diffusely infiltrative tumors (type IV; n  12; mean
SUV, 4.3  2.1). When the SUVs of the primary tumors
were compared with macroscopic types, a statistically sig-
nificant difference in mean SUV was found between type I
and the rest of the 3 macroscopic tumor types (P 0.0001).
Lymph Node Staging
Using histopathology as a gold standard for lymph node
metastasis, N1 disease was present in 53 (65%), N2 in 32
TABLE 1
Patient Characteristics





















Histology of primary tumors in EGC
WD tubular adenocarcinoma 5
MD tubular adenocarcinoma 3
PD tubular adenocarcinoma 3
Signet ring cell carcinoma 6
Histology of primary tumors in AGC
WD tubular adenocarcinoma 1
MD tubular adenocarcinoma 22
PD tubular adenocarcinoma 36
Signet ring cell carcinoma 4
Lymphoepitheliomalike carcinoma 1





WD  well differentiated; MD  moderately differentiated; PD 
poorly differentiated.
Mean age of patients was 56.6 y; range was 32–82 y.
FIGURE 1. EGC, Bormann type I. PET images demonstrate
focus of increased 18F-FDG uptake on sagittal (A) and axial (B)
views, and CT shows protruding mass (arrow) (C) in posterior
wall of antrum of stomach.
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(40%), and N3 in 6 (7%) of 81 patients. 18F-FDG PET had
a sensitivity, specificity, accuracy, PPV, and NPV of 34%
(18/53), 96% (27/28), 56% (45/81), 95% (18/19), and 44%
(27/62), respectively, for N1 disease and 34% (11/32), 96%
(47/49), 72% (58/81), 85% (11/13), and 69% (47/68), re-
spectively, for N2 disease (Table 2). The corresponding
values for CT were 58% (31/53), 89% (25/28), 69% (56/81),
91% (31/34), and 53% (25/47), respectively, for N1 and
44% (14/32), 86% (42/49), 69% (56/81), 67% (14/21), and
70% (42/60), respectively, for N2 (Figs. 2 and 3). For N3
lymph node metastases, PET and CT had the same sensi-
tivity, specificity, accuracy, PPV, and NPV: 50% (3/6), 99%
(74/75), 95% (77/81), 75% (3/4), and 96% (74/77), respec-
tively (Fig. 4).
Although PET and CT showed sensitivities insufficient
for N staging, the sensitivity of CT was significantly higher
than that of PET for N1 disease. CT appeared to be more
sensitive than PET for N2 disease, but the difference was
not statistically significant. The N2 lymph nodes seen only
on CT numbered 6 and were between 8 and 10 mm in size.
The poorer sensitivity of PET for N2 disease could have
been due to a partial-volume averaging effect. Regardless of
the poor sensitivities for N1 and N2 disease, PET correctly
detected 3 of 22 false-negative N1 nodes and 3 of 18
false-negative N2 nodes on CT. This finding, by suggesting
that PET has value in identifying the additional patients
with lymph node metastases not seen on CT, seems impor-
tant. CT and PET had the same low sensitivity of 50% for
detecting N3 disease. On the other hand, PET and CT had
better specificities than sensitivities for N staging. The spec-
ificities of PET for N staging were not significantly different
from those of CT, although PET seemed to be slightly more
specific for N2 disease.
Both PET and CT had PPVs of more than 90% for N1
disease and the same highest NPV of 96% for N3 disease,
which was clearly affected by the prevalence of lymph node
disease in each group. For N2 disease, the PPV of PET was
higher than that of CT, but without statistical significance.
When the performance of 18F-FDG PET and CT for
lymph node staging was evaluated separately for EGC and
AGC, no difference in results was noted between both
tumors. In cases of EGC, it was difficult to assess the
significance of the low sensitivities for both PET and CT
because of the limited number of metastatic lymph nodes
seen in this subgroup. However, both PET and CT showed
the same high specificity of 100%.
TABLE 2
Performance of 18F-FDG PET and CT for Lymph Node Staging
Type of cancer Stage
Imaging
type Sensitivity Specificity Accuracy PPV NPV
Both EGC and AGC N1 PET 34% (18/53) 96% (27/28) 56% (45/81) 95% (18/19) 44% (27/62)
CT 58% (31/53) 89% (25/28) 69% (56/81) 91% (31/34) 53% (25/47)
N2 PET 34% (11/32) 96% (47/49) 72% (58/81) 85% (11/13) 69% (47/68)
CT 44% (14/32) 86% (42/49) 69% (56/81) 67% (14/21) 70% (42/60)
N3 PET 50% (3/6) 99% (74/75) 95% (77/81) 75% (3/4) 96% (74/77)
CT 50% (3/6) 99% (74/75) 95% (77/81) 75% (3/4) 96% (74/77)
EGC only (n  17) N1 PET 33% (1/3) 100% (14/14) 88% (15/17) 100% (1/1) 88% (14/16)
CT 33% (1/3) 100% (14/14) 88% (15/17) 100% (1/1) 88% (14/16)
N2 PET 0% (0/2) 100% (15/15) 88% (15/17) 88% (15/17)
CT 0% (0/2) 100% (15/15) 88% (15/17) 88% (15/17)
N3 PET 100% (17/17) 100% (17/17) 100% (17/17)
CT 100% (17/17) 100% (17/17) 100% (17/17)
AGC only (n  64) N1 PET 34% (17/50) 93% (13/14) 47% (30/64) 94% (17/18) 28% (13/46)
CT 60% (30/50) 79% (11/14) 64% (41/64) 91% (30/33) 35% (11/31)
N2 PET 37% (11/30) 94% (32/34) 67% (43/64) 85% (11/13) 63% (32/51)
CT 47% (14/30) 79% (27/34) 64% (41/64) 67% (14/21) 63% (27/43)
N3 PET 50% (3/6) 98% (57/58) 94% (60/64) 75% (3/4) 95% (57/60)
CT 50% (3/6) 98% (57/58) 94% (60/64) 75% (3/4) 95% (57/60)
FIGURE 2. Patient with AGC and patho-
logically proven N1 metastasis. (A) 18F-
FDG PET shows mass with increased 18F-
FDG uptake in body of stomach without
perigastric lymph node metastasis. (B)
Perigastric lymph node (arrow) is noted on
CT. Sensitivity of CT is significantly higher
than that of PET for N1 disease.
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Other Findings
Two patients had metastases that were missed on PET
and CT but identified at surgery. One of these patients had
peritoneal seeding nodules, and the other had a mediastinal
lymph node metastasis.
DISCUSSION
Mass screening programs based on barium studies or
endoscopy have contributed to the detection of gastric can-
cer at earlier stages and, consequently, have improved long-
term survival rates (8). After detection, surgical resection
for localized disease is considered to be the only treatment
option with curative potential. Although endoscopic ultra-
sonography is excellent for locoregional staging, patient
discomfort and tumor stenosis limit its use (9). Other than
endoscopic ultrasonography, CT has been widely used as
the first-line imaging modality to determine the resectability
of gastric cancer. It evaluates a fat plane between the
primary tumor and an adjacent organ such as liver or pan-
creas to help the surgeon decide whether the tumor is
resectable. CT also plays an important role in assessing the
presence of peritoneal carcinomatosis, which is one of the
most common causes of futile laparotomies. However, the
limited accuracy of CT is well known and prevents differ-
entiation between metastatic and enlarged benign lymph
nodes (10,11).
The presence of lymph node metastases is considered to
be one of the most important prognostic factors in gastric
cancer. Other than the prognostic information, accurate
staging of lymph node disease is necessary in planning the
extent of lymph node dissection for the management of
patients with resectable disease. However, whether a cura-
tive resection should include an extended (D2) instead of a
limited (D1) lymph node dissection is unclear (12–16).
Bonenkamp et al. reported that patients with D2 lymph node
resection have a higher operative mortality rate, more com-
plications, and a longer postoperative hospital stay (17).
Those authors proposed that D2 lymph node dissection not
be used routinely in patients with gastric cancer. However,
a 5-y survival rate of 20%–39.2% was reported in a review
of the survival data of patients who had undergone D2
dissection for the curative resection of N2 disease (13). The
benefit from D2 dissection was found to be substantial,
offering long-term survival in patients with N2 disease (18).
Moreover, because no adjuvant therapy after D1 dissection
has been shown to be more effective than D2 dissection
alone, it was recommended as the only treatment modality
to achieve curative results for N2 disease. So far, we lack a
method capable of staging N disease accurately enough to
enable decision making on the extent of lymph node dis-
section.
In this study, we compared the diagnostic performance of
18F-FDG PET with that of CT for the evaluation of lymph
FIGURE 3. N2 metastasis (arrow) in region of common he-
patic artery on 18F-FDG PET sagittal (A) and axial (B) views and
on CT (C). For N2 disease, CT appears to be more sensitive than
PET, whereas PET appears more specific than CT.
FIGURE 4. Two N3 metastases (arrows)
in left paraaortic space on 18F-FDG PET (A)
and CT (B). Both PET and CT are insensi-
tive but highly specific for N3 disease.
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node metastases using histopathology as a gold standard.
Despite its high specificity, PET was less sensitive than CT
for the detection of N1 disease, probably because the spatial
resolution of PET was too low to discriminate perigastric
lymph nodes from primary tumors. Actually, the presence
or absence of N1 disease may not make a difference in
patients with AGC because all will undergo at least D1
dissection. What appears to be of clinical importance is the
determination of N2 or N3 disease status, because the pres-
ence of N2 disease may change the extent of lymph node
dissection from D1 to D2 or more, and the curative potential
of surgery may be decreased given evidence of N3 disease.
Our results showed that both modalities have low sensitiv-
ities for assessing N2 and N3 disease. The absence of lymph
node metastases in N2 or N3 groups on CT or PET appears
to be insufficient for determining the extent of lymph node
dissection. On the other hand, PET and CT showed high
specificities for N2 disease. The specificity of PET was
higher than that of CT, but without statistical significance.
Given the high specificity of 18F-FDG PET for N2 disease,
at least D2 lymph node dissection is needed to achieve
curative resection when N2 disease is evident on PET. The
same holds true for the presence of N3 disease on both
18F-FDG PET and CT. The high specificity, 99%, for PET
and CT may play an important role in extending the degree
of lymphadenectomy or reducing futile laparotomies in
cases of paraaortic lymph node metastasis. In contrast to the
results in N1 and N2 diseases, PET and CT showed the
same performance for N3 disease. It seems that the low
prevalence (6%) of N3 metastasis in this study may be
inadequate to accurately compare the diagnostic perfor-
mance of 2 modalities.
Because of mass screening programs, EGC accounts for
a significant portion of gastric cancers—up to 20%. The
prognosis of EGC is excellent with radical gastrectomy, and
the reported cumulative 5-y survival rate exceeds 95%
regardless of the status of lymph node metastases (19). This
success in survival has introduced the concept of minimally
invasive treatment with no or limited lymph node dissection
in the management of EGC. Endoscopic mucosal resection,
laparoscopic surgery, or limited resection by open surgery
for gastric cancer has been proposed as the initial treatment
of choice in some patients with EGC (20–22). However, the
application of minimally invasive surgery is limited in
lymphadenectomy and may result in tumor recurrence.
Therefore, the preoperative staging of lymph node status is
particularly important in selecting patients who would ben-
efit from minimally invasive surgery. N2 disease needs
invasive surgery with extended lymph node dissection
rather than minimally invasive surgery with limited lymph
node dissection. The presence of N1 disease is important
when deciding on the type of minimally invasive surgery for
EGC, unlike AGC. Endoscopic mucosal resection is indi-
cated for EGC tumors without lymph node involvement,
and laparoscopic or open gastrectomy with limited lymph
node dissection would be sufficient for mucosal cancer with
lymph node metastases (23). On the basis of our results, the
low sensitivities of both PET and CT appear to be problem-
atic in terms of detecting N1 disease. In contrast, PET
showed a very high specificity for N1 disease, and limited
lymph node dissection rather than endoscopic mucosal re-
section should be encouraged for patients with N1 disease
on PET.
It is well known that 18F-FDG uptake is low in some
histologic types of gastric cancer, such as signet ring cell
and mucinous carcinomas, because of an extracellular or
intracellular mucin component (24). Our data also appeared
to show relatively lower 18F-FDG uptake in signet ring cell
carcinoma than in moderately or poorly differentiated tubu-
lar adenocarcinoma. However, the number of cases with
signet ring histology was too small for statistical signifi-
cance to be drawn. In addition to our sensitive reading for
the detection of primary tumors on PET, we believe that the
small number of patients with signet ring cell carcinoma
could be reason for the high detection rate, 98%, for AGC
in this study. Low 18F-FDG uptake was also reported in
poorly differentiated types of primary lesions and was at-
tributed to the low concentration of cancer cells (6). In this
study, the mean SUV of poorly differentiated tubular ade-
nocarcinomas appeared to be lower than that of moderately
differentiated tumors, but the difference was not statistically
significant. We also found that poorly differentiated tubular
adenocarcinomas showed an especially wide spectrum of
18F-FDG uptake, from low to intense. Other factors besides
histologic grade seemed to affect the degree of 18F-FDG
uptake in poorly differentiated tubular adenocarcinomas.
Further studies are needed, including studies of the effect of
detailed histologic features on 18F-FDG uptake in these
tumors. Of the macroscopic types of primary tumors, type I
showed significantly greater 18F-FDG uptake than did the
other 3 types. The mass-forming growth of type I may have
been associated with the high 18F-FDG uptake observed in
this macroscopic type.
CONCLUSION
18F-FDG PET is as accurate as CT for detecting primary
tumors of the stomach in either EGC or AGC. Until now, no
imaging modality had been available to enable decision
making on the extent of lymphadenectomy in patients with
gastric cancer. Our study showed that the low sensitivities
of PET and CT are insufficient to resolve this issue although
PET can detect some additional lymph node metastases not
seen on CT. Nevertheless, PET and CT show high speci-
ficities for N disease, and the specificities of PET are the
same as or higher than those of CT. Evidence of N1 disease
on PET may change endoscopic mucosal resection to a
more aggressive surgical approach in patients with EGC.
The high specificity of 18F-FDG PET for N2 disease may
play an important role in avoiding limited lymph node
dissection for advanced disease. Finally, N3 disease on PET
may indicate the need for further aggressive lymphadenec-
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tomy or reduce the number of futile laparotomies in cases of
paraaortic lymph node metastasis.
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